Skip to main content
    M

    Monte Rosa Therapeutics Inc (GLUE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.16
    -0.21 (-2.24%)

    Market Cap: $800.67M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Monte Rosa Therapeutics Inc (GLUE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Monte Rosa Therapeutics reported revenue of $123.67M for the fiscal year ended Dec 31, 2025, up 63.5% from the year before. That year, net income was -$38.63M with a net margin of -31.2%, operating cash flow was -$22.80M and free cash flow was -$27.50M. The quarter ended Sep 30, 2026 had revenue of $54.37M and net income of $3.06M.

    Revenue and Margins

    The operating margin was -43.8% in the fiscal year ended Dec 2025.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$123.67M+63.5%100.0%-43.8%-31.2%
    Dec 2024$75.62MN/A100.0%-107.3%-96.1%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$123.67M$75.62M$0$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$72.00K
    Gross profit$123.67M$75.62M$0$0$0$0-$72.00K
    Research and development$141.50M$121.56M$111.27M$85.06M$57.16M$24.00M$7.35M
    Operating income-$54.21M-$81.11M-$143.31M-$112.38M-$72.88M-$28.01M-$7.99M
    Net income-$38.63M-$72.70M-$135.35M-$108.50M-$73.96M-$35.88M-$8.02M
    EBITDA-$44.31M-$72.58M-$138.00M-$108.52M-$71.87MN/A-$7.67M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$54.37M$8.97M$4.21M$2.78M$12.77M$23.19M$84.93M$60.65M$9.22M$4.70M$1.06M$8.75M
    Gross profit$54.37M$8.97M$4.21M$2.78M$12.77M$23.19M$84.93M$60.65M$9.22M$4.70M$1.06M-$1.85M
    Operating income-$1.94M-$49.13M-$50.03M-$49.72M-$32.98M-$15.55M$44.04M$13.00M-$26.53M-$32.64M-$34.95M-$34.86M
    Net income$3.06M-$43.40M-$44.50M-$46.13M-$27.08M-$12.29M$46.88M$13.44M-$23.86M-$30.31M-$31.97M-$33.25M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $4.40M by $125.49M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$448.66M$438.73M$303.75M$342.39M$366.33M$49.38M$11.09M
    Current assets$393.19M$377.44M$236.21M$275.89M$348.67M$43.59M$9.76M
    Cash and equivalents$129.88M$224.25M$128.10M$54.91M$346.07M$41.70M$6.00M
    Total liabilities$215.60M$215.80M$124.50M$70.98M$18.81M$30.34M$23.24M
    Short-term debt$4.40M$3.71M$3.16M$3.13MN/AN/A$750.00K
    Shareholder equity$233.06M$222.94M$179.25M$271.41M$347.51M$48.73M-$12.15M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$697.73M$691.16M$736.43M$448.66M$459.84M$359.59M$393.20M$438.73M$315.08M$344.11M$266.75M$303.75M
    Total liabilities$201.52M$203.88M$214.51M$215.60M$214.00M$91.51M$118.04M$215.80M$109.62M$119.44M$114.23M$124.50M
    Cash and equivalents$45.18M$90.10M$159.86M$129.88M$208.34M$69.43M$78.53M$224.25M$125.58M$108.85M$99.75M$128.10M
    Shareholder equity$496.21M$487.28M$521.92M$233.06M$245.84M$268.08M$275.16M$222.94M$205.46M$224.67M$152.52M$179.25M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$22.80M$42.00M-$43.80M-$92.47M-$59.36M-$23.05M-$6.17M
    Capital expenditures$4.70M$3.99M$19.04M$12.91M$9.73M$3.39M$1.39M
    Free cash flow-$27.50M$38.01M-$62.84M-$105.38M-$69.09M-$26.44M-$7.56M
    Share repurchases$357.00K$641.00K$116.00K$364.00K$231.00K$440.00KN/A
    Investing cash flow-$101.83M-$44.45M$88.80M-$219.22M-$9.65M-$3.39M-$1.39M
    Financing cash flow$30.35M$98.89M$27.49M$20.47M$377.56M$60.06M$15.00M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$40.98M-$44.11M-$37.37M-$43.01M$100.43M-$34.72M-$45.49M$128.92M-$20.99M-$27.77M-$38.16M$29.63M
    Capital expenditures$1.56M$4.72M$1.87M$767.00K$651.00K$1.70M$1.59M$183.00K$399.00K$2.02M$1.38M$1.69M
    Free cash flow-$42.54M-$48.84M-$39.24M-$43.78M$99.78M-$36.41M-$47.08M$128.74M-$21.39M-$29.79M-$39.55M$27.95M
    Last 12 quarters

    Frequently Asked Questions About GLUE

    What is Monte Rosa Therapeutics' annual revenue?

    Monte Rosa Therapeutics reported revenue of $123.67M for the fiscal year ended Dec 31, 2025.

    How fast is Monte Rosa Therapeutics' revenue growing?

    Revenue was up 63.5% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Monte Rosa Therapeutics profitable?

    No. Monte Rosa Therapeutics reported net income of -$38.63M for the fiscal year ended Dec 31, 2025, with a net margin of -31.2%.

    How much free cash flow does GLUE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$22.80M minus capital expenditures of $4.70M produced free cash flow of -$27.50M.

    How much debt does Monte Rosa Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $4.40M and cash and equivalents of $129.88M.